Table 3.
Correlative analysis between tumor proportion score, combined positive score, and tumor response according to imRECIST
| Variable | CR or PRa) | SD or PD | p-value |
|---|---|---|---|
| TPS | |||
| ≥ 1 (n=31) | 4 (12.9) | 27 (87.1) | > 0.99 |
| < 1 (n=8) | 1 (12.5) | 7 (87.5) | |
| TPS | |||
| ≥ 20 (n=12) | 3 (25.0) | 9 (75.0) | 0.159 |
| < 20 (n=27) | 2 (7.4) | 25 (92.6) | |
| TPS | |||
| ≥ 50 (n=8) | 3 (37.5) | 5 (62.5) | 0.049 |
| < 50 (n=31) | 2 (6.5) | 29 (93.5) | |
| CPS | |||
| ≥ 1 (n=37) | 4 (10.8) | 33 (89.2) | 0.243 |
| < 1 (n=2) | 1 (50.0) | 1 (50.0) | |
| CPS | |||
| ≥ 20 (n=21) | 3 (14.3) | 18 (85.7) | > 0.99 |
| < 20 (n=18) | 2 (11.1) | 16 (88.9) | |
| CPS | |||
| ≥ 50 (n=13) | 3 (23.1) | 10 (76.9) | 0.310 |
| < 50 (n=26) | 2 (7.7) | 24 (92.3) |
Values are presented as number (%). imRECIST, immune-modified Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TPS, tumor proportion score; CPS, combined positive score.
a)
Include a patient who showed CR after initial PD with the use of pembrolizumab beyond PD.